Solifenacin
Back to searchMolecule Structure
Scientific Name
Solifenacin
Description of the Drug
Solifenacin is a muscarinic antagonist with antispasmodic properties used to treat urge urinary incontinence, urgency, and urinary frequency associated with an overactive bladder.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01591
http://www.drugbank.ca/drugs/DB01591
Brand Name(s)
Vesicare
Company Owner(s)
Cipla Ltd, Alkem Laboratories Ltd, Sunshine Lake Pharma Co Ltd, Qilu Pharmaceutical Co Ltd, Watson Laboratories Inc, Zydus Pharmaceuticals Usa Inc, Graviti Pharmaceuticals Private Ltd, Ajanta Pharma Ltd, Astellas Pharma Us Inc, Accord Healthcare Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Muscarinic acetylcholine receptor M3 | SINGLE PROTEIN | ANTAGONIST | CHEMBL245 |
Muscarinic acetylcholine receptor M2 | SINGLE PROTEIN | ANTAGONIST | CHEMBL211 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL188493 | ||
DrugBank | DB01591 | ||
PubChem: Thomson Pharma | 16501406 | 16440595 | |
PubChem | 154059 | ||
LINCS | LSM-45423 | ||
Nikkaji | J1.594.869H | ||
BindingDB | 50344284 | 50370682 | |
EPA CompTox Dashboard | DTXSID3048289 | ||
DrugCentral | 2457 | ||
ChemicalBook | CB81179756 | ||
Guide to Pharmacology | 7483 | ||
rxnorm | VESICARE | SOLIFENACIN SUCCINATE | SOLIFENACIN |
ChEBI | 135530 | ||
ZINC | ZINC000003936683 |